What the second year on tirzepatide actually looks like

A friend at month 14 of tirzepatide asked me what the next year looks like. I realized I'd never written about this and that almost nothing online does either. The first year is documented to death. The second year is where the more interesting questions are, and almost no one talks about them.

Here's what I told her, based on watching people who've been on it longer.

The first thing that happens is the plateau. For most people, weight loss slows materially around month nine to twelve. The dramatic monthly drops you saw in months three through six become small monthly drops, then no monthly drops, then small monthly drops in either direction. This isn't a problem. It's a feature. The medication is doing what it's supposed to do, which is helping you find a new set point that your body can hold.

The mistake people make at month twelve is treating the plateau as failure. They push the dose higher, expecting the previous trajectory to continue. Most of the time, this just gives them more side effects without more weight loss. Some of the time, it works for another month or two and then they plateau at a slightly lower number, having paid more in side effects to get there.

The right move at month twelve, for most people, is to ask whether they're at a weight that works. Not "ideal" weight. Functional weight. Can you do the things you want to do? Are your labs good? Is your sleep good? If yes, the plateau is the answer. You're done losing. The next phase is keeping it.

That phase is what year two is mostly about.

Maintenance dose is the term you'll hear and the part that's underspecified. There isn't a standard maintenance dose for tirzepatide. The trial data on long-term use is still being generated. What patients and prescribers are figuring out empirically is that most people do best on a lower dose than they were on at peak weight loss. Someone who lost weight on 10mg often holds it well on 5mg or 7.5mg. Some people hold on 2.5mg. The patient and the prescriber work it out together over a few months of stepping down and watching what happens.

The second-year body is also not the first-year body. Most people lose some lean mass in year one, especially if they didn't add resistance training. By year two, the lean mass loss matters more than it did in year one because your metabolic rate is now meaningfully lower. The same dose holds the same weight, but if you were eating around the medication's appetite suppression in year one without paying attention to protein and resistance work, year two is when you start to notice what got lost in the process. Adding strength training in year two is harder than adding it in year one, but it's the highest-leverage thing most people can do.

The other thing that comes up in year two is the question of whether to come off. The reasons people consider it: cost, the residual side effects that never fully went away (some people still have nausea on shot day at month 14), the inconvenience of weekly injections, the existential question of whether they're "really" doing it themselves. Some of these are good reasons. Some are not.

The cost reason is increasingly answerable in 2026. Foundayo (oral, $149/month cash) launched in April. Generic semaglutide is coming sometime in the next 18 months as patents start to expire. The brand pricing pressure is real. If cost is the binding constraint, wait six months and the calculation may look different.

The "really doing it myself" reason is the one I push back on most often. The medication is a tool. Insulin is also a tool. SSRIs are tools. Glasses are tools. The instinct that you should solve a metabolic problem without a metabolic intervention because of some inner narrative about character is one of the things that kept us as a society from treating obesity as a chronic condition for decades. If the medication works, the medication works. The morality wasn't the issue.

The residual side effects reason is fair. If you're still uncomfortable on shot day at month 14, that's worth a conversation with your prescriber. Sometimes a dose reduction fixes it. Sometimes a switch to a different molecule (semaglutide instead of tirzepatide, or vice versa) does. Sometimes the answer is to come off and accept some regain.

What I told my friend specifically: stop treating year two as more of year one. The metrics change. Body composition matters more than weight. Labs matter more than the scale. The maintenance dose is its own conversation. And the longer arc, three years out and beyond, is one we're all figuring out together because the medication hasn't been around long enough for anyone to have a confident answer. That's not a reason to be anxious. It's a reason to pay attention.

The first year is the easy year. The work shows up later.